Literature DB >> 30775283

Scaling up isoniazid preventive therapy in Zimbabwe: has operational research influenced policy and practice?

K C Takarinda1,2, R C Choto1, T Mutasa-Apollo1, C Chakanyuka-Musanhu3, C Timire1,2, A D Harries2,4.   

Abstract

Setting: Following the operational research study conducted during the isoniazid preventive therapy (IPT) pilot phase in Zimbabwe, recommendations for improvement were adopted by the national antiretroviral therapy (ART) programme.
Objectives: To compare before (January 2013-June 2014) and after the recommendations (July 2014-December 2015), the extent of IPT scale-up and IPT completion rates, and after the recommendations the risk factors for IPT non-completion, in 530 ART clinics. Design: Retrospective cohort study.
Results: People living with the human immunodeficiency virus newly initiating IPT increased every quarter (Q), from 585 in Q 1, 2013 to 4246 in Q 4, 2015, with 5648 new IPT initiations in the 18 months before the recommendations compared to 20 513 in the 18 months after the recommendations were made. The number of ART clinics initiating IPT increased from 10 (2%) in Q 1, 2013 to 198 (37%) in Q 4, 2015. Overall IPT completion rates were 89% in the post-recommendation period compared with 81% in the pilot phase (P < 0.001). After adjusting for confounders, being lost to follow-up from clinic review visits 1 year prior to IPT initiation was associated with a higher risk of not completing IPT, while having synchronised IPT and ART resupplies was associated with a lower risk. Conclusions: Implementation of recommendations from the initial operational research study have improved IPT scale-up in Zimbabwe.

Entities:  

Keywords:  HIV; IPT; Zimbabwe; antiretroviral treatment; operational research

Year:  2018        PMID: 30775283      PMCID: PMC6361487          DOI: 10.5588/pha.18.0051

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  6 in total

1.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

Review 2.  Viral load monitoring as a tool to reinforce adherence: a systematic review.

Authors:  Kimberly Bonner; Alyssa Mezochow; Teri Roberts; Nathan Ford; Jennifer Cohn
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

3.  The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.

Authors:  Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

4.  Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.

Authors:  Jonathan E Golub; Paul Pronyk; Lerato Mohapi; Nkeko Thsabangu; Mosa Moshabela; Helen Struthers; Glenda E Gray; James A McIntyre; Richard E Chaisson; Neil A Martinson
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

5.  Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.

Authors:  Ankur Gupta; Robin Wood; Richard Kaplan; Linda-Gail Bekker; Stephen D Lawn
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

6.  Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe.

Authors:  K C Takarinda; R C Choto; A D Harries; T Mutasa-Apollo; C Chakanyuka-Musanhu
Journal:  Public Health Action       Date:  2017-03-21
  6 in total
  5 in total

1.  Implementation of tuberculosis preventive treatment among people living with HIV, South Sudan.

Authors:  Andrew T Boyd; Dennis Kenyi Lodiongo; John Mondi Benson; Shambel Aragaw; Margaret Semira Pasquale; Habtamu Ayalneh; Robert Olemukan; Isaac Avaku; Nicholas Baabe; Victoria Achut; Helen Chun; Sudhir Bunga
Journal:  Bull World Health Organ       Date:  2020-10-28       Impact factor: 9.408

2.  Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey.

Authors:  Collins Timire; John Z Metcalfe; Joconiah Chirenda; Jerod N Scholten; Barbara Manyame-Murwira; Mkhokheli Ngwenya; Ronnie Matambo; Kelvin Charambira; Herbert Mutunzi; Nico Kalisvaart; Charles Sandy
Journal:  Int J Infect Dis       Date:  2019-07-27       Impact factor: 12.074

3.  Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015.

Authors:  Richard Makurumidze; Tsitsi Mutasa-Apollo; Tom Decroo; Regis C Choto; Kudakwashe C Takarinda; Janet Dzangare; Lutgarde Lynen; Wim Van Damme; James Hakim; Tapuwa Magure; Owen Mugurungi; Simbarashe Rusakaniko
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

4.  Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.

Authors:  Muthoni Karanja; Leonard Kingwara; Philip Owiti; Elvis Kirui; Faith Ngari; Richard Kiplimo; Maurice Maina; Enos Masini; Elizabeth Onyango; Catherine Ngugi
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

5.  Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018.

Authors:  Kudakwashe C Takarinda; Anthony D Harries; Tsitsi Mutasa-Apollo; Charles Sandy; Regis C Choto; Simbarashe Mabaya; Cephas Mbito; Collins Timire
Journal:  BMJ Open       Date:  2020-04-06       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.